PE20221324A1 - Agonistas del tlr7 - Google Patents

Agonistas del tlr7

Info

Publication number
PE20221324A1
PE20221324A1 PE2022000859A PE2022000859A PE20221324A1 PE 20221324 A1 PE20221324 A1 PE 20221324A1 PE 2022000859 A PE2022000859 A PE 2022000859A PE 2022000859 A PE2022000859 A PE 2022000859A PE 20221324 A1 PE20221324 A1 PE 20221324A1
Authority
PE
Peru
Prior art keywords
alkyl
tlr7 agonists
compounds
dione
purine
Prior art date
Application number
PE2022000859A
Other languages
English (en)
Inventor
Stephen E Webber
James Richard Appleman
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of PE20221324A1 publication Critical patent/PE20221324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a compuestos de formula I, en donde: R1 y R2 son -H, -OH, -O-C(O)-R8 o -F; R3 es -OH, o -O-C(O)-R8; R4 es -H, -OH, -O-C(O)-R8 o -alquilo; R5 es -H, -OH, -O-C(O)-R8,-alquilo, -O-alquilo, -NH2 o -NHR8; R6 es -H, -alquilo, -C(H)=CH2, -C(H)=CH-alquilo, entre otras opciones; y, R7 es -H, -OH, -OCH3, -SH o -Cl. Entre los compuestos preferidos tenemos los siguientes: 2-Amino-9-((2R,3R,5S)-3-hidroxi-5-((S)-1- hidroxipropil)tetrahidrofuran-2-il)-7-(prop-2-in-1-il)-7,9- dihidro-1H-purina-6,8-diona; 2-Amino-9-((2R,3R,5S)-3-hidroxi-5- ((S)-1-hidroxibut-3-in-1-il)tetrahidrofuran-2-il)-7-(prop2-in-1-il)-7,9-dihidro-1H-purina-6,8-diona; entre otros. Estos compuestos son agonistas del TLR7 y son empleados en el tratamiento de enfermedades como el cancer y las enfermedades infecciosas.
PE2022000859A 2019-11-26 2020-11-25 Agonistas del tlr7 PE20221324A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26
PCT/US2020/062344 WO2021108649A1 (en) 2019-11-26 2020-11-25 Tlr7 agonists

Publications (1)

Publication Number Publication Date
PE20221324A1 true PE20221324A1 (es) 2022-09-09

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000859A PE20221324A1 (es) 2019-11-26 2020-11-25 Agonistas del tlr7

Country Status (17)

Country Link
US (2) US11692005B2 (es)
EP (1) EP4065155A4 (es)
JP (1) JP2023503996A (es)
KR (1) KR20220150879A (es)
CN (1) CN115427063A (es)
AU (1) AU2020391487A1 (es)
BR (1) BR112022010165A2 (es)
CA (1) CA3163093A1 (es)
CL (1) CL2022001377A1 (es)
CO (1) CO2022008835A2 (es)
CR (1) CR20220282A (es)
EC (1) ECSP22049906A (es)
IL (1) IL293293A (es)
MX (1) MX2022006307A (es)
PE (1) PE20221324A1 (es)
TW (1) TW202134240A (es)
WO (1) WO2021108649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
AU5845594A (en) 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
IL129118A0 (en) 1996-10-16 2000-02-17 Icn Pharmaceuticals Purine L-nucleosides analogs and uses thereof
AU784374C (en) 1999-11-12 2007-06-28 Pharmasset Inc Synthesis of 2'-deoxy-L-nucleosides
SK11922002A3 (sk) 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
GEP20084545B (en) 2003-09-05 2008-11-25 Anadys Pharmaceuticals Inc Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
KR101320008B1 (ko) 2004-12-17 2013-10-18 애나디스 파마슈티칼스, 인코포레이티드 ３，５-이치환 및 ３，５，７-삼치환된-３Ｈ-옥사졸로 및３Ｈ-티아졸로 〔４，５-ｄ〕피리미딘-2-온 화합물 및 이의전구약물
MX2010001785A (es) 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
WO2010111290A1 (en) 2009-03-23 2010-09-30 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
CN104661683A (zh) 2011-11-09 2015-05-27 埃森德生物制药有限公司 免疫调节缀合物
ES2910446T3 (es) 2014-07-09 2022-05-12 Birdie Biopharmaceuticals Inc Combinaciones anti-PD-L1 para tratar tumores
CR20170237A (es) 2014-12-08 2017-08-10 Hoffmann La Roche Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
EP3845227A1 (en) 2015-03-16 2021-07-07 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
MY183036A (en) 2016-12-20 2021-02-08 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
BR112020023866A2 (pt) 2018-05-25 2021-04-06 Primmune Therapeutics, Inc. Agonistas de tlr7

Also Published As

Publication number Publication date
CN115427063A (zh) 2022-12-02
EP4065155A4 (en) 2023-11-29
CO2022008835A2 (es) 2022-07-19
AU2020391487A1 (en) 2022-07-07
CL2022001377A1 (es) 2023-04-10
CA3163093A1 (en) 2021-06-03
CR20220282A (es) 2022-11-28
JP2023503996A (ja) 2023-02-01
IL293293A (en) 2022-07-01
US11692005B2 (en) 2023-07-04
KR20220150879A (ko) 2022-11-11
US20240116974A1 (en) 2024-04-11
BR112022010165A2 (pt) 2022-08-09
WO2021108649A1 (en) 2021-06-03
US20210155652A1 (en) 2021-05-27
EP4065155A1 (en) 2022-10-05
ECSP22049906A (es) 2022-07-29
MX2022006307A (es) 2022-08-22
TW202134240A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
CL2022003648A1 (es) Conjugados de una molécula de unión celular con análogos de camptotecina
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
EA202190006A1 (ru) Пуриноновые соединения и их применение при лечении рака
CL2022002828A1 (es) Inhibidores de kras tricíclicos fusionados.
PE20210255A1 (es) Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
PE20220387A1 (es) Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
CL2012001688A1 (es) Compuestos derivados 2,7 - disustituida - 1 - (4-halo fenil) -1,2,5,6 - tetrahidroisoquinolin - 3(4h) - ona; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades proliferativas.
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
PE20200701A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porcion heterobiarilo, conjugados de estos y metodos y usos de estos
PE20221324A1 (es) Agonistas del tlr7
PE20210131A1 (es) COMPUESTOS TETRAHIDRO-1H-PIRAZINO[2,1-a]ISOINDOLILQUINOLINA PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES
GT201200242A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
PE20231108A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
PE20191082A1 (es) Inhibidores de la tirosina quinasa de bruton
CO2020016131A2 (es) Agonistas de tlr7
CO2023016212A2 (es) Derivados de triazina y su uso en el tratamiento del cáncer
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
CR20160462A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CL2022003055A1 (es) Antagonistas del receptor de adenosina a2a